PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Biosimilar Denosumab Matches Reference on Lumbar Spine Bone Density

denosumabbiosimilar denosumabRANKL inhibitorpostmenopausal osteoporosisbone mineral densitymeta-analysisgeriatric pharmacyimmunogenicity Geriatrics / Geriatric Pharmacy

Background Information

Biosimilar denosumab matches reference in treating osteoporosis.

Denosumab is used to manage osteoporosis in postmenopausal women, and understanding the efficacy of its biosimilar is crucial for safe, cost-effective treatment options. Both reference and biosimilar denosumab showed similar lumbar spine bone mineral density (BMD), though reference denosumab had a slight advantage in hip BMD. This study indicates biosimilar denosumab is a viable alternative to reference denosumab, but further studies are needed for long-term safety and efficacy in diverse populations. Biosimilar denosumab may be as effective as reference denosumab in postmenopausal osteoporosis.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Zainab S, Zaheer L, Sheikh AR, Khalid MS, Arshad MZ, Khatoon A, Zahra N, Ahmed E, Zakir E, Fatima E, Tariq A, Abbas K, Kanwal A, Haq UU, Khan AA, Suman S

Citation: Zainab S, Zaheer L, Sheikh AR, et al. Comparative efficacy of biosimilar denosumab and reference denosumab in treatment of postmenopausal osteoporosis: a systematic review and meta-analysis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2026. doi:10.1007/s00198-026-08159-3

Article Links: PubMed · Journal / DOI

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.